Imeglimin is a first-in-class oral hypoglycemic agent used for the treatment of T2DM and targets mitochondrial bioenergetics to ameliorate insulin resistance and enhance β-cell function. It has also been shown to improve glycemic control when added to metformin or sitagliptin monotherapy in T2DM inadequately controlled with these drugs alone. We conducted a real World observational study (n=115) for 1 year follow up for the patients in whom Imeglimin was used as a third line agent (GLYCEM-IN Trial). The mean FPG at baseline was 280.8 mg/dl (±61.5, 95% CI 268.6 to 293.1) which reduced to 176.2 mg/dl (±64.9, 95% CI 163.3 to 189), significant reduction by -104.7 mg/dl (p<0.0001). The mean PPG at baseline was 326.4 mg/dl (±64.7, 95% CI 313.6 to 339.2) which reduced to 209.3 mg/dl (±75.3, 95% CI 194.3 to 224.3), significant reduction by -117.7 mg/dl (p<0.0001). The mean HbA1c at baseline was 8.7% (±0.86, 95% CI 8.5 to 8.8) which reduced to 8.2% (±0.77, 95% CI 8.1 to 8.4), significant reduction by -0.45 (p<0.0001). The mean PPG at baseline was 1.1 mg/dl (±0.15, 95% CI 0.14 to 1.13) which reduced to 0.7 mg/dl (±0.1, 95% CI 0.68 to 0.72), significant reduction by -0.39 mg/dl (p<0.0001). Imeglimin demonstrated significant efficacy as a third line treatment for T2DM. It notably decreased mean fasting plasma glucose by 104.7 mg/dl and postprandial glucose by 117.7 mg/dl. HbA1c levels showed a meaningful reduction of 0.45%. These results suggest that Imeglimin effectively enhances glycemic control in T2DM patients inadequately managed with other monotherapies.
A. Gupta: None. R. Duggal: None.
